Sudden_death_due_to_disease_flare_with_luteinizing_hormone-releasing_hormone_agonist_therapy_for_carcinoma_of_the_prostate._Luteinizing_hormone-releasing_hormone_agonist_therapy_for_prostate_cancer_is_a_new_method_of_management_for_metastatic_disease._During_the_initial_1_to_2-week_period_of_administration_an_increase_in_serum_testosterone_concentration_can_lead_to_an_exacerbation_of_clinical_symptoms_(flare_phenomenon)._Two_patients_are_summarized_who_received_luteinizing_hormone-releasing_hormone_agonist_therapy_without_flare_blockade_and_died_suddenly_during_month_1_of_therapy._A_review_of_765_patients_in_9_series_found_10.9%_who_suffered_disease_flare_and_15_who_died_during_disease_flare._Of_these_17_patients_12_were_similar_to_our_2._These_data_suggest_that_any_patient_placed_on_luteinizing_hormone-releasing_hormone_agonist_therapy_for_prostate_cancer_merits_some_form_of_flare_blockade_during_the_initial_1_or_2_months_of_therapy.